A phase i pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer

Sang Joon Shin, Hei Cheul Jeung, Joong Bae Ahn, Sun Young Rha, Jae Kyung Roh, Kyung Soo Park, Dal Hyun Kim, Chin Kim, Hyun Cheol Chung

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Summary: We conducted a phase I trial of the antiangiogenic agent 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate (CKD-732). Our aims were to determine the maximum tolerated dose (MTD), pharmacokinetics (PK), and safety profiles as well as identify the biologically active dose (BAD) from ex vivo pharmacodynamics (PD) and biomarkers of CKD-732. Using a dose escalation schedule, 19 patients with refractory solid tumors were enrolled at dose levels of CKD-732 ranging from 1 to 15 mg/m2 given twice weekly for 2 weeks followed by a 1-week rest. No treatment-related deaths occurred in this study. Confusion and insomnia were dose-limiting toxicities (DLTs), and MTD was 15 mg/m2. The area under the concentration-time curve (AUC) and maximum concentration (Cmax) increased dose dependently with increasing doses. The BAD was 5 mg/m2 according to ex vivo PD. A decrement in soluble vascular endothelial growth factor receptor-3 (sVEGF-3) level was correlated with a reduction in tumor size (r=0.54, P=0.045). The results from this study showed an MTD of 15 mg/m2 and a BAD of 5 mg/m2.

Original languageEnglish
Pages (from-to)650-658
Number of pages9
JournalInvestigational New Drugs
Volume28
Issue number5
DOIs
Publication statusPublished - 2010 Oct 1

Fingerprint

Angiogenesis Inhibitors
Maximum Tolerated Dose
Pharmacokinetics
Vascular Endothelial Growth Factor Receptor-3
Confusion
Neoplasms
Sleep Initiation and Maintenance Disorders
Appointments and Schedules
Biomarkers
Safety
CKD732
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Shin, Sang Joon ; Jeung, Hei Cheul ; Ahn, Joong Bae ; Rha, Sun Young ; Roh, Jae Kyung ; Park, Kyung Soo ; Kim, Dal Hyun ; Kim, Chin ; Chung, Hyun Cheol. / A phase i pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. In: Investigational New Drugs. 2010 ; Vol. 28, No. 5. pp. 650-658.
@article{854f2a93c0e34e5cb98fc21734fb41f9,
title = "A phase i pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer",
abstract = "Summary: We conducted a phase I trial of the antiangiogenic agent 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate (CKD-732). Our aims were to determine the maximum tolerated dose (MTD), pharmacokinetics (PK), and safety profiles as well as identify the biologically active dose (BAD) from ex vivo pharmacodynamics (PD) and biomarkers of CKD-732. Using a dose escalation schedule, 19 patients with refractory solid tumors were enrolled at dose levels of CKD-732 ranging from 1 to 15 mg/m2 given twice weekly for 2 weeks followed by a 1-week rest. No treatment-related deaths occurred in this study. Confusion and insomnia were dose-limiting toxicities (DLTs), and MTD was 15 mg/m2. The area under the concentration-time curve (AUC) and maximum concentration (Cmax) increased dose dependently with increasing doses. The BAD was 5 mg/m2 according to ex vivo PD. A decrement in soluble vascular endothelial growth factor receptor-3 (sVEGF-3) level was correlated with a reduction in tumor size (r=0.54, P=0.045). The results from this study showed an MTD of 15 mg/m2 and a BAD of 5 mg/m2.",
author = "Shin, {Sang Joon} and Jeung, {Hei Cheul} and Ahn, {Joong Bae} and Rha, {Sun Young} and Roh, {Jae Kyung} and Park, {Kyung Soo} and Kim, {Dal Hyun} and Chin Kim and Chung, {Hyun Cheol}",
year = "2010",
month = "10",
day = "1",
doi = "10.1007/s10637-009-9287-8",
language = "English",
volume = "28",
pages = "650--658",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "5",

}

A phase i pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. / Shin, Sang Joon; Jeung, Hei Cheul; Ahn, Joong Bae; Rha, Sun Young; Roh, Jae Kyung; Park, Kyung Soo; Kim, Dal Hyun; Kim, Chin; Chung, Hyun Cheol.

In: Investigational New Drugs, Vol. 28, No. 5, 01.10.2010, p. 650-658.

Research output: Contribution to journalArticle

TY - JOUR

T1 - A phase i pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer

AU - Shin, Sang Joon

AU - Jeung, Hei Cheul

AU - Ahn, Joong Bae

AU - Rha, Sun Young

AU - Roh, Jae Kyung

AU - Park, Kyung Soo

AU - Kim, Dal Hyun

AU - Kim, Chin

AU - Chung, Hyun Cheol

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Summary: We conducted a phase I trial of the antiangiogenic agent 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate (CKD-732). Our aims were to determine the maximum tolerated dose (MTD), pharmacokinetics (PK), and safety profiles as well as identify the biologically active dose (BAD) from ex vivo pharmacodynamics (PD) and biomarkers of CKD-732. Using a dose escalation schedule, 19 patients with refractory solid tumors were enrolled at dose levels of CKD-732 ranging from 1 to 15 mg/m2 given twice weekly for 2 weeks followed by a 1-week rest. No treatment-related deaths occurred in this study. Confusion and insomnia were dose-limiting toxicities (DLTs), and MTD was 15 mg/m2. The area under the concentration-time curve (AUC) and maximum concentration (Cmax) increased dose dependently with increasing doses. The BAD was 5 mg/m2 according to ex vivo PD. A decrement in soluble vascular endothelial growth factor receptor-3 (sVEGF-3) level was correlated with a reduction in tumor size (r=0.54, P=0.045). The results from this study showed an MTD of 15 mg/m2 and a BAD of 5 mg/m2.

AB - Summary: We conducted a phase I trial of the antiangiogenic agent 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol hemioxalate (CKD-732). Our aims were to determine the maximum tolerated dose (MTD), pharmacokinetics (PK), and safety profiles as well as identify the biologically active dose (BAD) from ex vivo pharmacodynamics (PD) and biomarkers of CKD-732. Using a dose escalation schedule, 19 patients with refractory solid tumors were enrolled at dose levels of CKD-732 ranging from 1 to 15 mg/m2 given twice weekly for 2 weeks followed by a 1-week rest. No treatment-related deaths occurred in this study. Confusion and insomnia were dose-limiting toxicities (DLTs), and MTD was 15 mg/m2. The area under the concentration-time curve (AUC) and maximum concentration (Cmax) increased dose dependently with increasing doses. The BAD was 5 mg/m2 according to ex vivo PD. A decrement in soluble vascular endothelial growth factor receptor-3 (sVEGF-3) level was correlated with a reduction in tumor size (r=0.54, P=0.045). The results from this study showed an MTD of 15 mg/m2 and a BAD of 5 mg/m2.

UR - http://www.scopus.com/inward/record.url?scp=77956058589&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956058589&partnerID=8YFLogxK

U2 - 10.1007/s10637-009-9287-8

DO - 10.1007/s10637-009-9287-8

M3 - Article

C2 - 19585083

AN - SCOPUS:77956058589

VL - 28

SP - 650

EP - 658

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 5

ER -